CPT® Code 80349

Official Description

Cannabinoids, natural

Common Language Description

The CPT® Code 80349 refers to a laboratory test specifically designed to measure natural cannabinoids present in biological samples such as meconium stool, urine, serum, or plasma. Cannabinoids are chemical compounds that occur naturally in the marijuana plant, known scientifically as Cannabis sativa. Among these compounds, tetrahydrocannabinol (THC) is the most notable due to its psychoactive properties, which significantly influence the brain's limbic system. This area of the brain is crucial for functions related to memory, cognition, and psychomotor performance, as well as the mesolimbic pathways that are involved in the perception of reward and pain. THC is characterized by its fat solubility and has a long elimination half-life, meaning it can remain detectable in the body for extended periods. Specifically, cannabinoids can be identified in urine for several weeks following exposure, while they may be present in serum or plasma for up to 12 hours. The collection of samples for this test involves obtaining a blood sample through venipuncture, acquiring a urine sample via random void or catheterization, and collecting meconium stool from a diaper. The testing process utilizes quantitative liquid chromatography-tandem mass spectrometry to accurately detect THC and its metabolite, 9-carboxy-THC, providing essential information regarding cannabinoid exposure.

1. Indications

The laboratory test represented by CPT® Code 80349 is indicated for the assessment of natural cannabinoids in various biological samples. The following conditions or situations may warrant the performance of this test:

Assessment of Exposure This test is utilized to evaluate potential exposure to cannabinoids, particularly in individuals where such exposure may have clinical implications.
Monitoring Substance Use It may be employed in monitoring patients for substance use, especially in contexts such as rehabilitation or legal situations.
Clinical Evaluation The test can assist healthcare providers in making informed clinical decisions regarding treatment plans for patients with suspected cannabinoid use.

2. Procedure

The procedure for conducting the test under CPT® Code 80349 involves several key steps to ensure accurate measurement of cannabinoids in the specified biological samples. Each step is critical for obtaining reliable results.

Sample Collection The first step involves the collection of biological samples. A blood sample is obtained through a procedure known as venipuncture, which involves inserting a needle into a vein to draw blood. Urine samples can be collected either through random voiding by the patient or via catheterization, depending on the clinical scenario. Additionally, meconium stool samples are collected from a diaper, particularly in newborns, to assess cannabinoid exposure during gestation.
Sample Preparation Once the samples are collected, they must be properly prepared for analysis. This preparation may involve processes such as centrifugation to separate plasma or serum from blood cells, ensuring that the samples are suitable for testing.
Testing Methodology The prepared samples are then subjected to quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS). This advanced analytical technique allows for the precise detection and quantification of THC and its metabolite, 9-carboxy-THC, in the samples. The use of LC-MS/MS is essential for achieving the sensitivity and specificity required for cannabinoid testing.

3. Post-Procedure

After the procedure, the samples are analyzed, and results are generated based on the presence and concentration of cannabinoids detected. Healthcare providers will interpret these results in the context of the patient's clinical history and current health status. It is important to note that the detection of cannabinoids may have implications for treatment decisions, legal considerations, or further diagnostic evaluations. Patients may not require specific post-procedure care related to the sample collection itself, but they should be informed about the potential implications of the test results and any necessary follow-up actions.

Short Descr	CANNABINOIDS NATURAL
Medium Descr	DRUG SCREENING CANNABINOIDS NATURAL
Long Descr	Cannabinoids, natural
Status Code	Not Valid for Medicare Purposes
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
APC Status Indicator	Code Not Recognized by OPPS when submitted on Outpatient Hospital Part B Bill Type (12x/13x)
Type of Service (TOS)	5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS)	T2D - Other tests - other
MUE	1

26	Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number.
90	Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
GZ	Item or service expected to be denied as not reasonable and necessary